NeuroMetrix, Inc.

Equities

NURO

US6412558800

Medical Equipment, Supplies & Distribution

Delayed Nasdaq Other stock markets 03:46:28 2024-04-25 pm EDT			5-day change	1st Jan Change
4.35 ^USD	+0.46%		+18.90%	+20.56%

Apr. 19	Sector Update: Health Care Stocks Advance Late Afternoon	MT
Apr. 19	Sector Update: Health Care Stocks Rise Friday Afternoon	MT

Neurometrix, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2021

April 22, 2021 at 07:00 am EDT

NeuroMetrix, Inc. announced earnings results for the first quarter ended March 31, 2021. For the first quarter, the company announced sales was USD 2.155 million compared to USD 2.172 million a year ago. Operating loss was USD 60,195 compared to USD 657,869 a year ago. Net loss was USD 59,783 compared to USD 657,371 a year ago.

Latest news about NeuroMetrix, Inc.

Sector Update: Health Care Stocks Advance Late Afternoon	Apr. 19	MT
Sector Update: Health Care Stocks Rise Friday Afternoon	Apr. 19	MT
NeuroMetrix Says Joshua Horowitz Joining Board, Terminates At-the-Market Equity Facility	Apr. 19	MT
Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board	Apr. 19	CI
NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy	Mar. 14	CI
Ephraim Fields Discloses his Views on NeuroMetrix	Feb. 27	CI
RS Fund Discloses its Views on NeuroMetrix	Feb. 26	CI
Transcript : NeuroMetrix, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
NeuroMetrix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
NeuroMetrix, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
NeuroMetrix Announces Review of Strategic Options to Promote Growth and Maximize Shareholder Value	Feb. 13	CI
Neurometrix, Inc. Reports Encouraging Results from Pilot Clinical Trial of Quell®? in Post-Acute Covid-19 Syndrome (Long Covid)	Dec. 12	CI
NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy	Dec. 05	CI
Sector Update: Health Care Stocks Advance in Late Afternoon Trading	Nov. 20	MT
Sector Update: Health Care Stocks Advance in Afternoon Trading	Nov. 20	MT
NeuroMetrix Announces 1-for-8 Reverse Stock Split; Shares Fall	Nov. 20	MT
Transcript : NeuroMetrix, Inc., Q3 2023 Earnings Call, Oct 26, 2023	23-10-26
NeuroMetrix, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	23-10-26	CI
North American Morning Briefing : Nasdaq Futures -2-	23-10-26	DJ
NeuroMetrix, Inc. and the National Fibromyalgia Association to Collaborate to Improve the Quality of Life for People Living with Fibromyalgia	23-10-02	CI
Transcript : NeuroMetrix, Inc., Q2 2023 Earnings Call, Jul 27, 2023	23-07-27
NeuroMetrix, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-07-27	CI
North American Morning Briefing : Nasdaq Futures -2-	23-07-20	DJ
NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia	23-07-11	CI
NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting	23-06-07	CI

Chart NeuroMetrix, Inc.

Duration

Period

More charts

Company Profile

NeuroMetrix, Inc. is a commercial-stage healthcare company that develops and commercializes neurotechnology devices to address unmet needs in the chronic pain and diabetes markets. The Company's products are wearable or hand-held medical devices enabled by proprietary consumables and software solutions that include mobile apps, enterprise software and cloud-based systems. The Company has two commercial brands. Quell is a wearable neuromodulation platform. DPNCheck is a point-of-care screening test for peripheral neuropathy. It operates two product categories: Diagnostic technology and Therapeutic technology. Diagnostic technology product category is engaged in point-of-care peripheral neuropathy assessment. Therapeutic technology product category is engaged in wearable neuromodulation for chronic pain syndromes. Its patients control and personalize the technology via a mobile phone application, and their utilization and certain clinical metrics may be tracked in the Quell Health Cloud.

Sector

Medical Equipment, Supplies & Distribution

Calendar

2024-04-24 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Medical Equipment, Supplies & Distribution

	1st Jan change	Capi.
NEUROMETRIX, INC.	+20.56%	8.6M
ABBOTT LABORATORIES	-2.95%	185B
MEDTRONIC PLC	-3.88%	107B
BECTON, DICKINSON AND COMPANY	-5.30%	67.55B
DEXCOM, INC.	+11.27%	54.6B
CENCORA, INC.	+16.75%	47.42B
HOYA CORPORATION	+3.86%	42.24B
WEST PHARMACEUTICAL SERVICES, INC.	+5.17%	28.24B
METTLER-TOLEDO INTERNATIONAL, INC.	+1.53%	26.42B
TERUMO CORPORATION	+12.40%	25.66B

Other Medical Equipment, Supplies & Distribution